Alphatec Holdings Inc (ATEC)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Alphatec Holdings Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 9.50 $ — 16% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
6 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 29.6% passed
- More than 10% revenue growth is expected for the coming year 16.6% passed
- Share count grows by less than 3% a year 13.2% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 25.3% failed
- Gross margin at 40% or higher and without meaningful erosion 69.6% passed
- Goodwill from acquisitions does not grow faster than revenue 9.5% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 414 m passed
- Return on capital at 15% or higher, or up versus two years ago -14.4% failed
- Insiders hold at least 10% or are net buyers 20.5% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 66.9% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.32 | 0.26 – 0.39 | 882 | 536.4% | 10 |
| 12/31/2027 | 0.59 | 0.48 – 0.73 | 1,030 | 85.3% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.12 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.23 | – | 177 | 28.10 | -18.90 | 11 | 7 |
| 2025: Q1 | -0.35 | – | 169 | 22.20 | -30.70 | -5 | -15 |
| 2025: Q2 | -0.27 | – | 186 | 27.50 | -22.20 | 16 | 3 |
| 2025: Q3 | -0.19 | – | 197 | 30.40 | -14.50 | 14 | 5 |
| 2025: Q4 | -0.14 | – | 213 | 20.40 | -10.20 | 21 | 10 |
| 2026: Q1 | -0.22 | – | 192 | 13.60 | -17.60 | 1 | -11 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 120 | -15 | -30 | -3.53 | -10 | -42 | 94 |
| 2017 | 102 | -9 | -2 | -0.17 | -9 | -27 | 85 |
| 2018 | 92 | -22 | -29 | -0.82 | -26 | 18 | 129 |
| 2019 | 113 | -47 | -57 | -1.09 | -33 | 44 | 170 |
| 2020 | 145 | -59 | -79 | -1.18 | -46 | 130 | 261 |
| 2021 | 243 | -128 | -143 | -1.49 | -73 | 79 | 572 |
| 2022 | 351 | -147 | -151 | -1.46 | -75 | -35 | 521 |
| 2023 | 482 | -173 | -187 | -1.54 | -78 | 102 | 805 |
| 2024 | 612 | -136 | -162 | -1.13 | -45 | 9 | 776 |
| 2025 | 764 | -82 | -143 | -0.96 | 45 | 36 | 791 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Alphatec Holdings, Inc., ein Medizintechnikunternehmen, entwirft, entwickelt und verbessert Technologien zur chirurgischen Behandlung von Wirbelsäulenerkrankungen in den USA und international.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 913 |
| Headquarters | Carlsbad, CA |
| Address | 1950 Camino Vida Roble, 92008 Carlsbad, United States |
| Phone | 760 431 9286 |
| Website | atecspine.com |
| IPO Date | 2. Jun 2006 |
| ISIN | US02081G2012 |
| Stock Split | 1:12 on 08/25/2016 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Patrick S. Miles | Chairman, CEO & President | 1966 |
| J. Todd Koning | Executive VP & CFO | 1973 |
| Scott Lish | Chief Operating Officer | 1981 |
| David P. Sponsel | Executive Vice President of Sales | 1979 |
| Craig E. Hunsaker | Executive Vice President of People & Culture | 1964 |
| Robert Judd | VP of Finance and Investor Relations & Controller | – |
| Tyson Eliot Marshall | General Counsel & Corporate Secretary | 1974 |
| Ali Shorooghi | Senior Vice President of Marketing | 1986 |
| Jonathan Allen | Executive Vice President of Commercial Operations | 1960 |
| Luiz Pimenta M.D., Ph.D. | Chief Medical Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.